Effects of anthocyanin supplementation on serum lipids, glucose, markers of inflammation and cognition in adults with increased risk of dementia

-a pilot study-

Anne Katrine Bergland1,2*, Hogne Soennesyn1, Ingvild Dalen3, Ana Rodriguez-Mateos4, Rolf Kristian Berge5, Lasse Melvaer Giil6, Lawrence Rajendran7,8, Richard Siow9, Michele Tassotti4,10, Alf Inge Larsen2,11, Dag Aarsland1,8

1Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
2Department of Clinical Sciences, University of Bergen, Bergen, Norway
3Section of Biostatistics, Department of Research, Stavanger University Hospital, Stavanger, Norway
4School of Life Course Sciences, Faculty of Medicine and Life Sciences, Department of Nutritional Sciences, King’s College, London, UK
5The Lipid Research Group, Department of Clinical Sciences, University of Bergen, Bergen, Norway
6Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway
7Institute of Psychiatry, Psychology & Neuroscience, King’s College, London, UK
8Dementia Research Institute, King’s College London, UK
9School of Cardiovascular Medicine and Sciences, British Heart Foundation Centre of Research Excellence, Faculty of Life Sciences and Medicine, King’s College London, UK
10Department of Food & Drugs, University of Parma, Parma, Italy
11Department of Cardiology, Stavanger University Hospital, Stavanger, Norway

*Corresponding Author

Anne Katrine Bergland
Stavanger University Hospital, Department of Internal Medicine
Postboks 8100
4068 Stavanger
Norway
Telephone: 0047 91595103
Fax: 0047 51515161
e-mail: anne.katrine.bergland@sus.no

Keywords: Mild Cognitive Impairment, MCI, Anthocyanins, Lipids, Inflammation markers

https://register.clinicaltrials.gov
ClinicalTrial.gov NCT02409446

Abstract word count: 219
Main text word count: 3106
Number of figures and tables: 14, including supplementary material
Abstract

Background:
Anthocyanins may protect against cardiovascular related cognitive decline and dementia.

Objective:
Open-label study to measure changes in serum lipids, glucose, glycosylated hemoglobin (HbA1c), and markers of inflammation after anthocyanin supplementation in people with increased risk of dementia. As a secondary endpoint we examined potential changes in a battery of cognitive test in the anthocyanin group (AG).

A total of 27 individuals with mild cognitive impairment (MCI) (n=8) or stable non-obstructive coronary artery disease (CAD) (n=19) consumed two Medox® capsules, each containing 80 mg of natural purified anthocyanins, twice daily for 16 weeks. They provided blood samples and performed a short battery of cognitive tests. Twenty healthy normal controls (NC) (n=20) provided blood samples, but did not receive any intervention and did not perform cognitive tests.

Results:
There was a significant difference between groups for CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted) (RANTES). In addition, total cholesterol and triglycerides were significantly increased in the anthocyanin group. Improvements in memory and executive test scores were observed. No adverse effects were reported.

Conclusion:
The results of this pilot study were largely inconclusive with regard to the potential protective effects of anthocyanin supplementation. However, anthocyanins were well tolerated, and compliance was high. Larger, placebo-controlled studies to explore the potential effects of anthocyanins on dementia risk are encouraged.
Introduction

Anthocyanins, a subclass of the flavonoids, are found in foods such as berries and fruits (Neveu et al., 2010). Anthocyanins have been shown in previous studies to have a number of positive health effects, such as improving the blood lipid profile (Qin et al., 2009; Li et al., 2015), and also fasting serum glucose and glycosylated hemoglobin (HbA1c) in diabetic patients (Li et al., 2015; Yang et al., 2017), and have anti-inflammatory effects (Xia et al., 2007; Spencer et al., 2012; Spagnuolo et al., 2017). Anthocyanins can improve endothelial and vascular function (Rodriguez-Mateos et al., 2013; Rodriguez-Mateos et al., 2016; Rodriguez-Mateos et al., 2019), and can cross the blood-brain barrier (Faria et al., 2014) and thus may reduce neurodegenerative and cerebrovascular changes and possibly protect against cognitive decline and dementia. Interestingly, some studies have found that food-based anthocyanins can improve memory functioning in older adults with mild cognitive impairment (MCI) (Krikorian et al., 2010a; Krikorian et al., 2010b; Hein et al., 2019). However, these studies were based on relatively small samples, and had a short duration. In addition, food-based anthocyanin supplementation leads to heterogeneity, i.e. variations in types of food sources, concentration, and dose of anthocyanins.

In this exploratory open-label pilot study, we aimed as a primary endpoint to examine potential changes in dementia-relevant mechanisms after 16 weeks of treatment with purified anthocyanin containing capsules, in people with increased risk of dementia. As a secondary endpoint we also explored the potential change in a battery of cognitive tests.
Methods

Material
Participants were recruited from the outpatient Memory and Cardiology clinics at Stavanger University Hospital in Norway during 2015 and 2016. Eligible for this study were patients with MCI or mild dementia and/or stable non-obstructive coronary artery disease (CAD). Potential participants identified at the respective outpatient clinics were contacted for a telephone interview by a study doctor, regarding inclusion and exclusion criteria. Participants were also recruited from the Dementia Disease Initiation (DDI) study (Fladby et al., 2017). Inclusion criteria were age ≥ 50 years and being on stable medication, including nutraceuticals for the past 3 months, and either a) confirmed CAD without physiologically significant stenosis evaluated by coronary angiography, or b) having MCI or mild dementia according to ICD 10 (World Health Organization, 1992).

Exclusion criteria were moderate to severe dementia (operationalized as a Mini-Mental Status Exam (MMSE) (Folstein et al., 1975) score < 24), clinically significant depression (15–item Geriatric Depression Scale (GDS-15) (Mitchell et al., 2010) score ≥7), unstable coronary artery disease, heart failure in need of treatment, having taken Medox® during the past 3 months, using Warfarin, heparin or non-vitamin K antagonist oral anticoagulants (NOAC), inflammatory illnesses such as rheumatoid arthritis and other severe illness with < 5 years expected survival. Any treatment with vitamins, minerals or nutraceuticals had to have remained stable for the last 3 months prior to inclusion and during the study. Healthy normal controls (NC) (n=20) recruited from the staff at Stavanger University Hospital and through acquaintances, were ≥ 50 years, had stable medication, and had not been taking Medox® for the last 3 months. This group provided blood samples at inclusion and 16 weeks later, but did not take Medox® or other interventions, and did not perform the cognitive test battery. The rationale for including this comparison group was to have a reference group with respect to any observed changes in the blood analyses in the intervention group.

Ethics
All participants provided written informed consent, and the study has been approved by the Regional Ethics Committee (Approval 2014/1966). The study has been registered at Clin.Gov.Trial (NCT02409446)

Intervention, design, and assessment

Intervention
The participants were given open-label Medox® capsules, provided free of charge by the manufacturer Medpalett AS, Sandnes, Norway. Medox® capsules, which contain specific quantities of natural purified anthocyanins from bilberry (Vaccinium myrtillus) and blackcurrant (Ribes nigrum), have been used previously in human studies (Karlsen et al., 2007). The production of the Medox® capsule (Hassellund et al., 2013), and its anthocyanin content (Qin et al., 2009) have been described previously.

The capsules were dispensed at inclusion in the study, and the participants were instructed to consume two 80 mg anthocyanin capsules twice daily for a total daily intake of 320 mg anthocyanins for 16 weeks. This dosage was chosen because it has previously been shown to have biological effects (Qin et al., 2009; Zhu et al., 2011; Li et al., 2015) and found to be safe in use (Qin et al., 2009). A review found that doses up to 640 mg/day showed no adverse events (Wallace et al., 2016).
Participants were instructed to maintain their dietary and lifestyle habits in order to avoid interferences in the study results.

**Design and assessment**
At inclusion, all participants underwent a physical examination, including standardized blood pressure measurement, electrocardiogram (ECG), and blood tests. In addition a cognitive test battery (see below) was administered, including the MMSE and GDS-15. Following standardized procedures, participants provided blood samples in the morning after having been fasting for at least 8 hours, before and after 16 weeks of treatment. They were contacted by telephone after 8 weeks regarding safety and compliance.

**Blood sampling and analyses**
Blood was collected, centrifugated, and stored at -80°C until analysis according to standardized procedures. The serum samples were analysed for lipids (total cholesterol, triglycerides, HDL- and LDL-cholesterol) and fasting glucose using Architect c16000 TM (Abbott Diagnostics, IL, USA) and HbA1c using Variant II turbo (BioRad, California, USA) at Stavanger University Hospital.

Markers of inflammation were analysed after completion of the study by The Lipid Research Group, Department of Clinical Sciences, University of Bergen, Bergen, Norway. Concentrations of cytokines were measured in serum using the Bio-Plex Pro™ Human Cytokine 8-plex assay (Cat.: M50000007A) which included GM-CSF, IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10 and TNF-α, in addition to five Bio-Plex Pro Human Cytokine single-plexes: MCP-1 (Cat.: 171B5021M), RANTES (Cat.: 171B5025M), G-CSF (Cat.: 171B5017M), IL-17 (Cat.: 171B5014M) and IL-1β (Cat.:171B5001M). All plexes were manufactured by Bio-Rad (Hercules, CA, USA). The cytokines were detected by the Bio-Plex™ 200 System and determined with the Bio-Plex Manager Software 6.1. The samples were prepared as described in the protocol (Cat.: 10014905) with a dilution factor of three.

Anthocyanin metabolites were measured in plasma after completion of the study at Department of Nutritional Sciences, School of Life Course Sciences, Faculty of Medicine and Life Sciences, King’s College, London, using a method based on microelution solid phase extraction followed by liquid chromatography and mass spectrometry, using authentic standards, as previously described with some modifications (Feliciano et al., 2016). The detection of plasma (poly)phenol metabolites was performed on a Exactive™ Orbitrap Mass Spectrometer (Thermo Scientific, CA, USA) after separation on an Accela 1250 pump UHPLC system (Thermo Scientific, CA, USA). The autosampler injected 5 μL of each sample in a Zorbax Eclipse Plus RRHD column 2.1 × 50 mm, 1.8 m with a compatible Eclipse Plus guardcolumn 2.1 × 5 mm, 1.8 m (Agilent, Waldbronn, Germany). The mobile phase consisted of 0.1% HCOOH (solvent A) and acetonitrile with 0.1% HCOOH (solvent B) in a 10 min gradient program. Quantification analysis of the plasma (poly)phenols was done using Xcalibur 2.2 (Thermo Scientific, CA, USA).

**Cognitive tests**
Verbal memory function was assessed using the Norwegian adaptation of the Ten Word List Learning and Recall from the CERAD battery (Morris et al., 1989), a three part test; word list learning, word list delayed recall, and word list delayed recognition.
Executive functioning was assessed by the Trail making test (TMT) A and B (Reitan and Wolfson, 1985) and Stroop Golden (Golden, 1976). The Trail Making Tests A and B are tests of psychomotor speed and attention shifting (Ashendorf et al., 2008), while Stroop Golden is a test used to evaluate cognitive speed and inhibition (Scarpina and Tagini, 2017).
Safety
Participants were contacted by phone at week 8 to ask about potential side-effects and adverse events (AE). The safety blood tests included hemoglobin, thrombocytes, kidney function and liver function tests, which were measured at both baseline and study-end.

Compliance
Participants were contacted by phone at about week 8 and asked about adherence to the protocol. Specifically, they were asked whether they had been taking Medox® capsules as instructed, and they were reminded about keeping the empty blister packages. Protocol adherence was also assessed by collecting and counting the empty blister packages and leftover capsules at study-end.

Statistical analyses
Descriptive statistics are presented as medians and interquartile ranges (IQR), and illustrated using Box plots. Most data were not normally distributed and thus the main analyses were non-parametric. The Mann-Whitney U test and the Chi-square test were used for between-group comparisons. Changes from baseline to follow-up at 24 weeks within groups were analyzed with the Wilcoxon Signed Rank test. For all tests $p \leq 0.05$ was considered statistically significant. Supplementary parametric analyses were performed, from which we present means, standard deviations (SD), and p-values from paired and independent samples t-tests. The IBM SPSS statistical package version 24 was used for all statistical analyses.

Results
During the period May 2015 to September 2016, 33 participants started anthocyanin supplementation, of whom 27 (8 MCI and 19 CAD) completed the study (6 were excluded for administrative and logistical reasons) (Figure 1). The NC were included in the period December 2016 to February 2017. No subjects with mild dementia were included. Baseline characteristics are shown in Table 1.

Only IL-8, MCP-1, CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted) (RANTES) and TNF were available for statistical analyses, as the other inflammation markers did not reach measurement thresholds. The findings are summarized in Table 2. The only significant between-group difference was for $\Delta$RANTES (difference from baseline to study end) which decreased in the supplementation group and increased in the NC group (Table 2).

When analyzing the groups separately, significant increases were found in total cholesterol and triglycerides in the anthocyanin supplementation group (AG) from baseline to study end (Table 2), and MCP-1 which increased in the NC group (Table 2). No significant changes were found for fasting glucose and HbA1c in the AG group.

A total of 29 plasma anthocyanin metabolites were quantified (Table 3). When comparing the two groups, a statistically significant difference was found for two metabolites (o-Coumaric acid and Dihydroferulic acid-4-$O$-Sulfate), which both had a larger decrease in the AG than in the NC group (Table 3).
In the AG, there was a statistically significant increase in five of the metabolites (Pyrogallol-2-O-sulfate, Protocatechuic acid-3-O-sulfate, Pyrogallol-1-O-sulfate, Ferulic acid-4-O-β-D-glucuronide, Isoferulic acid-3-O-β-D-glucuronide) and a statistically significant decrease in five other metabolites (3-Hydroxyhippuric acid, 4-Hydroxybenzaldehyde, Dihydroferulic acid-4-O-Sulfate, m-Coumaric acid, o-Coumaric acid) after 16 weeks of anthocyanin consumption in comparison with baseline.

In the NC group, there was a statistically significant decrease in four metabolites (Protocatechuic acid, 3,4-Dihydroxyphenylacetic acid, 4-Hydroxybenzaldehyde and o-Coumaric acid), whereas there were no statistically significant increases in any of the metabolites.

The cognitive test scores improved in the intervention group, with improvements for CERAD learning (p=0.016), recall (p < 0.001) and recognition (p=0.05) (Table 4) and for STROOP test word (p < 0.001) and color (p = 0.044) (Table 4).

Overall, findings using parametric analyses differed only marginally from the non-parametric findings reported above (Table S1 to S2).

The compliance was good. More than 85% of the participants returned at least 90% of the empty blister packages. The anthocyanins were well tolerated, and none of the participants withdrew due to adverse effects. Blood tests taken for safety reasons were all within a clinically acceptable range. Increased bleeding tendency was not observed.

**Discussion**

In this pilot study anthocyanin supplementation was well tolerated, without any adverse events, and the compliance was good. This indicates that larger RCTs might be feasible, to confirm exploratory results in the current pilot study.

Our findings are somewhat inconclusive. While some cognitive improvements were observed in the AG, there were no significant changes in serum levels of some vascular risk factors for dementia; i.e. fasting glucose, Hba1c or pro-inflammatory cytokines. There was a non-significant decrease in serum levels of RANTES in the AG and a non-significant increase in the NC during the study period. However, the between-group difference in Δ serum levels of RANTES was statistically significant.

Furthermore, we observed a significant increase in serum levels of total cholesterol and triglycerides in AG. The lipid profile of the NC group did not change significantly, and since we have no information about statin use or use of other lipid lowering medications in the NC group, the observed difference should be interpreted cautiously. Previous studies using Medox® have shown a statistically significant increase in HDL-cholesterol (Qin et al., 2009;Zhu et al., 2011;Hassellund et al., 2013) and a decrease in LDL-cholesterol (Qin et al., 2009;Zhu et al., 2011). This is of clinical interest, as higher HDL-cholesterol is associated with lower cardiovascular risk (Barter et al., 2007), while high levels of total cholesterol, triglycerides and LDL are associated with higher cardiovascular risk (Stone et al., 2014). The differences in the findings between our study and these previous studies might be due to differences in participants, as well as in anthocyanin supplementation dose and duration, or other factors. Furthermore, other studies included dyslipidemic and hypercholesemic participants not using statins or any other lipid lowering treatment (Qin et al., 2009;Zhu et al.,
2011), whereas in our study, the median cholesterol at baseline in the intervention group was 4.0 mmol/l, in addition 70 % were taking statins or other lipid lowering medication.

Regarding the inflammation markers, RANTES promotes activation and migration of leukocytes and mediates neuroinflammation and brain microvascular dysfunction (Appay and Rowland-Jones, 2001; Dénes et al., 2010; Yilmaz and Granger, 2010). There was a significant between-group difference for ΔRANTES, although anthocyanin supplementation did not significantly reduce RANTES in the AG. Still, our results are consistent with similar findings in a randomised, double-blind trial in hypercholesterolemic individuals consuming purified anthocyanins for 24 weeks (Song et al., 2014), and in a parallel-designed, placebo-controlled trial (Karlsen et al., 2007). Other studies did not report a reduction of pro-inflammatory mediators after anthocyanin supplementation (Hassellund et al., 2013; Kent et al., 2015). Therefore, the anti-inflammatory effect of anthocyanins and the potential to reduce neuroinflammation and brain microvascular dysfunction associated with cognitive decline in adults at risk of dementia (Grammas, 2011) should be studied in larger randomized studies.

The beneficial effect of anthocyanins might possibly be due to their degradation products and metabolites (Feliciano et al., 2016) as absorption of intact anthocyanins is reported to be low (Zhong et al., 2017). Rodriguez-Mateos et al. quantified metabolites in plasma after blueberry consumption, and showed that anthocyanin-derived metabolites correlated with in vivo effects (Rodriguez-Mateos et al., 2013; Rodriguez-Mateos et al., 2019). Furthermore, circulating anthocyanin metabolites were shown to improve vascular function when injected in an in vivo model of vascular function, and cardiovascular benefits after consumption of anthocyanins were linked with anthocyanin metabolites as mediators of change in cellular gene programs (Rodriguez-Mateos et al., 2019).

In our study, we were able to measure a total of 29 anthocyanin metabolites. The results were conflicting, as we found various anthocyanin metabolites to be both significantly increasing and decreasing in the AG. In the NC group as well, we found significant changes. This is in line with findings in another study reporting an increase of some metabolites, and a decrease in others after ingestion of anthocyanins over time (Feliciano et al., 2016). A possible explanation for our results could be high inter-individual variability and the influence of the background diet on the concentration of these compounds in blood, as some of these metabolites could arise from the consumption of other anthocyanin-rich foods such as berries and red wine or other food components in the diet. It is also possible that the results could be related to the handling and analysis of the blood samples. As far as we know, the presence of anthocyanin metabolites in plasma after Medox® use is reported in only one other clinical study, where 8 out of 17 anthocyan metabolites were found to be significantly increased. However, this was analysed in blood samples collected 1-3 h after ingestion of the morning dose of anthocyanins (320 mg), and not after daily consumption and an overnight fast (Hassellund et al., 2013).

The improvement on several cognitive tests should be interpreted cautiously due to potential learning effects related to the relatively short test-retest interval, and the lack of a comparison group. Nonetheless, our results are in line with previous smaller studies involving participants with MCI, reporting improved cognition after ingestion of anthocyanins (Krikorian et al., 2010a; Krikorian et al., 2010b). Our results are also in line with the results of a randomized, double-blinded, placebo-controlled study reporting improved episodic memory after 3 months of anthocyanin supplementation (Whyte et al., 2018).
Intake of anthocyanin capsules in the dosage of 320 mg/day appears to be well tolerated and safe. None of the safety blood tests were found to be out of a clinically acceptable range or necessitating medical follow-up after study-end. This is consistent with previous studies (Karlsen et al., 2007; Qin et al., 2009).

The major limitations of this pilot study are the non-randomized open-label design, the small sample size, and the relatively short intervention period. Although all the participants were told not to change their lifestyle during the intervention period, we have no data on this. Further we had no detailed dietary assessment, and thus we cannot exclude the possibility of differences in the background diet between the groups before or during the study. However, the participants were instructed to maintain their dietary and lifestyle habits during the study period, and to take the capsules 30 minutes before or 120 minutes after meals, as concomitant ingestion of certain types of food may counteract the effect of flavonoids (Lorenz et al., 2007).

The NC were recruited separately and differed from the participants by being a healthy group that did not receive any intervention, and did not perform cognitive testing. Thus power calculations for further studies might be compromised. However, we provide descriptive statistics including variance measurements which may be helpful in planning sample size in later studies.

An important strength of our study is the well characterized combination of nutraceuticals used, which facilitates comparison with other studies regarding both source of anthocyanins and dosage. Of note, this is, to our knowledge, the first study on cognitive function in adults with increased risk of dementia where Medox® is being used as the source of anthocyanin. Thus our study might also facilitate investigation of the effect of different proprietary blueberry formulations, shown by Whyte et al. to be of importance (Whyte et al., 2018).

All things considered, adequately powered, randomized studies are warranted to better understand how anthocyanins and their metabolites may affect relevant mechanisms, including their possible protective role in epigenetic modifications that potentially benefit the aging brain and reduce the risk for dementia.

Acknowledgements

The authors would like to thank the research nurses Reidun Sikveland Meling and Jorunn Margrete Nilsen for their contribution in the conduction of the study. We thank Hellen Svalestad for her contribution to participant recruitment from the cardiology department, and Bjarne Hervik for his contribution in recruiting healthy normal controls.

Statement of Ethics

All participants provided written informed consent, and the study has been approved by the Regional Ethics Committee (Approval 2014/1966). The study has been registered at Clin.Gov.Trial (NCT02409446)

Disclosure Statement

Anne Katrine Bergland has received support for conference participation from Evonik.
Dr Aarsland has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health, and serves as paid consultant for H. Lundbeck and Axovant. This paper represents independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. None of the other authors have conflict of interest related to this article. None of the other authors have conflict of interest related to this article.

**Funding Sources**

The study was financed by a grant from Sandnes Sparebank, Sandnes, Norway and the Norwegian Health Association, grant number 7330. Medpalett, Sandnes, Norway contributed to the study by producing Medox® free of charge. Medpalett had no influence on the design or conduction of the study, the analyses and interpretation of data, or regarding the decision to publish the findings.

**Author Contributions**

DA, HS, AKB and AIL planned and designed the study. AKB conducted the study and the data collection. RKB did the serum analyses. MT and AMR did the plasma analyses. Statistical analyses of the data were done by AKB and ID. The original paper draft was written by AKB. DA, ID, AMR, RKB, AIL, LGM, LR, RS, MT and HS critically reviewed the paper.
References

Appay, V., and Rowland-Jones, S.L.J.T.I.I. (2001). RANTES: a versatile and controversial chemokine. 22, 83-87.

Ashendorf, L., Jefferson, A.L., O’connor, M.K., Chaisson, C., Green, R.C., and Stern, R.A. (2008). Trail Making Test errors in normal aging, mild cognitive impairment, and dementia. Archives of Clinical Neuropsychology 23, 129-137.

Barter, P., Gotto, A.M., Larosa, J.C., Maroni, J., Szarek, M., Grundy, S.M., Kastelein, J.J., Bittner, V., and Fruchart, J.-C. (2007). HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine 357, 1301-1310.

Dénes, Á., Humphreys, N., Lane, T.E., Grencis, R., and Rothwell, N.J.O.N. (2010). Chronic systemic infection exacerbates ischemic brain damage via a CCL5 (regulated on activation, normal T-cell expressed and secreted)-mediated proinflammatory response in mice. 30, 10086-10095.

Faria, A., Meireles, M., Fernandes, I., Santos-Buelga, C., Gonzalez-Manzano, S., Dueñas, M., De Freitas, V., Mateus, N., and Calhau, C. (2014). Flavonoid metabolites transport across a human BBB model. Food chemistry 149, 190-196.

Feliciano, R.P., Istas, G., Heiss, C., and Rodriguez-Mateos, A.J.M. (2016). Plasma and urinary phenolic profiles after acute and repetitive intake of wild blueberry. 21, 1120.

Fladby, T., Pålhaugen, L., Selnes, P., Waterloo, K., Bråthen, G., Hessen, E., Almdahl, I.S., Arntzen, K.-A., Auning, E., and Eliassen, C.F. (2017). Detecting at-risk alzheimer’s disease cases. Journal of Alzheimer's Disease 60, 97-105.

Folstein, M.F., Folstein, S.E., and Mchugh, P.R. (1975). “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research 12, 189-198.

Golden, C.J. (1976). Identification of brain disorders by the Stroop Color and Word Test. Journal of clinical psychology 32, 654-658.

Grammas, P.J.J.O.N. (2011). Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. 8, 26.

Hassellund, S., Flaa, A., Kjeldsen, S., Seljeflot, I., Karlsen, A., Erlund, I., and Rostrup, M. (2013). Effects of anthocyanins on cardiovascular risk factors and inflammation in pre-hypertensive men: a double-blind randomized placebo-controlled crossover study. Journal of human hypertension 27, 100-106.

Hein, S., Whyte, A.R., Wood, E., Rodriguez-Mateos, A., and Williams, C.M.J.T.J.O.G.S.A. (2019). Systematic review of the effects of blueberry on cognitive performance as we age.

Karlsen, A., Retterstøl, L., Laake, P., Paur, I., Kjølsrud-Bøhn, S., Sandvik, L., and Blomhoff, R. (2007). Anthocyanins inhibit nuclear factor-κB activation in monocytes and reduce plasma concentrations of pro-inflammatory mediators in healthy adults. The Journal of nutrition 137, 1951-1954.

Kent, K., Charlton, K., Roodeyrs, S., Batterham, M., Potter, J., Traynor, V., Gilbert, H., Morgan, O., and Richards, R. (2015). Consumption of anthocyanin-rich cherry juice for 12 weeks improves memory and cognition in older adults with mild-to-moderate dementia. European journal of nutrition, 1-9.

Krikorian, R., Nash, T.A., Shidler, M.D., Shukitt-Hale, B., and Joseph, J.A. (2010a). Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. British Journal of Nutrition 103, 730-734.
Krikorian, R., Shidler, M.D., Nash, T.A., Kalt, W., Vinqvist-Tymchuk, M.R., Shukitt-Hale, B., and Joseph, J.A. (2010b). Blueberry Supplementation Improves Memory in Older Adults†. *Journal of agricultural and food chemistry* 58, 3996-4000.

Li, D., Zhang, Y., Liu, Y., Sun, R., and Xia, M. (2015). Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients. *The Journal of nutrition* 145, 742-748.

Lorenz, M., Jochmann, N., Von Krosigk, A., Martus, P., Baumann, G., Stangl, K., and Stangl, V. (2007). Addition of milk prevents vascular protective effects of tea. *European heart journal* 28, 219-223.

Mitchell, A.J., Bird, V., Rizzo, M., and Meader, N. (2010). Diagnostic validity and added value of the Geriatric Depression Scale for depression in primary care: a meta-analysis of GDS30 and GDS15. *Journal of affective disorders* 125, 10-17.

Morris, J.C., Heyman, A., Mohs, R.C., Hughes, J.P., Van Belle, G., Fillenbaum, G., Mellits, E.D., and Clark, C. (1989). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology* 39, 1159-1165.

Neveu, V., Perez-Jiménez, J., Vos, F., Crespy, V., Du Chaffaut, L., Mennen, L., Knox, C., Eisner, R., Cruz, J., and Wishart, D.J.D. (2010). Phenol-Explorer: an online comprehensive database on polyphenol contents in foods. 2010.

Qin, Y., Xia, M., Ma, J., Hao, Y., Liu, J., Mou, H., Cao, L., and Ling, W. (2009). Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. *The American journal of clinical nutrition* 90, 485-492.

Reitan, R., and Wolfson, D. (1985). "The Halstead-Reitan neuropsychological test battery: therapy and clinical assessment". Tucson, AZ: Neuropsychological Press).

Rodriguez-Mateos, A., Istars, G., Boschek, L., Feliciano, R.P., Mills, C.E., Boby, C., Gomez-Alonso, S., Milenkovic, D., and Heiss, C.J.T.J.O.G.S.A. (2019). Circulating anthocyanin metabolites mediate vascular benefits of blueberries: insights from randomized controlled trials, metabolomics, and nutrigenomics.

Rodriguez-Mateos, A., Rendeiro, C., Bergillos-Meca, T., Tabatabaee, S., George, T.W., Heiss, C., and Spencer, J.P.J.T.a.J.O.C.N. (2013). Intake and time dependence of blueberry flavonoid–induced improvements in vascular function: a randomized, controlled, double-blind, crossover intervention study with mechanistic insights into biological activity. 98, 1179-1191.

Rodriguez-Mateos, A., Feliciano, R.P., Boeres, A., Weber, T., Dos Santos, C.N., Ventura, M.R., Heiss, C.J.M.N., and Research, F. (2016). Cranberry (poly) phenol metabolites correlate with improvements in vascular function: A double-blind, randomized, controlled, dose-response, crossover study. 60, 2130-2140.

Scarpina, F., and Tagini, S. (2017). The Stroop Color and Word Test. *Frontiers in Psychology* 8.

Song, F., Zhu, Y., Shi, Z., Tian, J., Deng, X., Ren, J., Andrews, M.C., Ni, H., Ling, W., Yang, Y.J.T., and Haemostasis (2014). Plant food anthocyanins inhibit platelet granule secretion in hypercholesterolaemia: Involving the signalling pathway of PI3K–Akt. 111, 981-991.

Spagnuolo, C., Moccia, S., and Russo, G.L. (2017). Anti-inflammatory effects of flavonoids in neurodegenerative disorders. *European journal of medicinal chemistry*.

Spencer, J.P., Vafeiadou, K., Williams, R.J., and Vauzour, D. (2012). Neuroinflammation: modulation by flavonoids and mechanisms of action. *Molecular aspects of medicine* 33, 83-97.
Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Merz, C.N.B., Blum, C.B., Eckel, R.H., Goldberg, A.C., Gordon, D., Levy, D., and Lloyd-Jones, D.M.J.O.T.a.C.O.C. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 63, 2889-2934.

Wallace, T.C., Slavin, M., and Frankenfeld, C.L. (2016). Systematic review of anthocyanins and markers of cardiovascular disease. *Nutrients* 8, 32.

Whyte, A., Cheng, N., Fromentin, E., and Williams, C.J.N. (2018). A randomized, double-blinded, placebo-controlled study to compare the safety and efficacy of low dose enhanced wild blueberry powder and wild blueberry extract (ThinkBlue™) in maintenance of episodic and working memory in older adults. 10, 660.

World Health Organization (1992). *The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines.* Geneva: World Health Organization.

Xia, M., Ling, W., Zhu, H., Wang, Q., Ma, J., Hou, M., Tang, Z., Li, L., and Ye, Q. (2007). Anthocyanin prevents CD40-activated proinflammatory signaling in endothelial cells by regulating cholesterol distribution. *Arteriosclerosis, thrombosis, and vascular biology* 27, 519-524.

Yang, L., Ling, W., Du, Z., Chen, Y., Li, D., Deng, S., Liu, Z., and Yang, L. (2017). Effects of Anthocyanins on Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Advances in Nutrition* 8, 684-693.

Yilmaz, G., and Granger, D.N.J.N.M. (2010). Leukocyte recruitment and ischemic brain injury. 12, 193-204.

Zhong, S., Sandhu, A., Edirisinghe, I., Burton-Freeman, B.J.M.N., and Research, F. (2017). Characterization of Wild Blueberry Polyphenols Bioavailability and Kinetic Profile in Plasma over 24-h Period in Human Subjects. 61, 1700405.

Zhu, Y., Xia, M., Yang, Y., Liu, F., Li, Z., Hao, Y., Mi, M., Jin, T., and Ling, W. (2011). Purified anthocyanin supplementation improves endothelial function via NO-cGMP activation in hypercholesterolemic individuals. *Clinical chemistry* 57, 1524-1533.
Figure 1

- Did not meet inclusion criteria = 16
- Had exclusion criteria = 27
- Did not want to participate = 23
- Included in a clinical trial involving medicinal product = 1
- Not reached by researcher = 2

- Did not meet inclusion criteria = 1
  - Participant had not been on stable medications for the last 3 months

- Had exclusion criteria = 1
- Not compliant to study protocol = 5
  - Not able to attend follow-up as scheduled = 2
  - Not able to ingest Medox® according to protocol = 3
Table 1 Baseline Characteristics

|                                | Active (n=27) Median (IQR) | Controls (n=20) Median (IQR) |
|--------------------------------|----------------------------|-------------------------------|
| Women, count (%)               | 9 (33)                     | 11 (55)                       |
| Age (years)                    | 61 (55 to 70)              | 58 (55 to 62)                 |
| CAD, count (%)                 | 19 (70)                    |                               |
| Education (years)              | 11.5 (10 to 14)            |                               |
| BMI                            | 27.7 (26.0 to 30.3)        |                               |
| Lipid lowering therapy, count (%) | 19 (70)               |                               |
| Acetylsalicylic acid, count (%) | 17 (63)                  |                               |
| Oral antidiabetic treatment count (%) | 3 (11)                  |                               |
| Dietary supplement, count (%)  | 18 (67)                    |                               |
Table 2 Changes from baseline to 16 weeks follow-up in serum variables, for participants with supplementation (active) and for control participants.

| Variable                  | Active (n = 27) | Control (n = 20) | Active vs Control |
|---------------------------|----------------|------------------|-------------------|
|                           | Median (IQR)   | Median (IQR)     | p*                |
|                           | p*             | p*               |
| Cholesterol (mmol/L)      |                | Cholesterol      |                   |
| Pre                       | 4.0 (3.1 to 5.5) | 5.1 (4.5 to 5.5) | 0.009             |
| Post                      | 4.6 (3.3 to 6.0) | 5.1 (4.6 to 5.6) | 0.009             |
| Diff                      | 0.2 (0.1 to 0.7) | 0.1 (-0.2 to 0.5) | 0.29              |
| HDL (mmol/L)              |                | HDL              |                   |
| Pre                       | 1.2 (1.0 to 1.4) | 1.5 (1.1 to 1.7) | 0.808             |
| Post                      | 1.2 (1.1 to 1.5) | 1.4 (1.2 to 1.8) | 0.808             |
| Diff                      | 0.0 (-0.1 to 0.1) | 0.1 (-0.1 to 0.1) | 0.21              |
| LDL (mmol/L)              |                | LDL<sup>n=19</sup> |                   |
| Pre                       | 2.4 (1.8 to 3.9) | 3.3 (2.9 to 3.9) | 0.209             |
| Post                      | 3.0 (1.8 to 4.3) | 3.3 (2.8 to 4.0) | 0.209             |
| Diff                      | 0.1 (-0.1 to 0.3) | 0.0 (-0.1 to 0.4) | 0.62              |
| Triglycerides (mmol/L)    |                | Triglycerides    |                   |
| Pre                       | 1.0 (0.7 to 1.4) | 0.9 (0.6 to 1.3) | 0.016             |
| Post                      | 1.0 (0.7 to 1.7) | 0.9 (0.6 to 1.8) | 0.016             |
| Diff                      | 0.1 (0.7 to 1.7) | 0.0 (-0.1 to 0.4) | 0.072             |
| Fasting glucose (mmol/L)  |                | Fasting glucose  |                   |
| Pre                       | 5.4 (4.9 to 5.6) | 5.3 (5.0 to 5.6) | 0.058             |
| Post                      | 5.5 (5.3 to 6.3) | 5.0 (4.8 to 5.7) | 0.058             |
| Diff                      | 0.2 (-0.1 to 0.4) | -0.2 (-0.4 to -0.03) | 0.009            |
| HbA1c (%)                 |                | HbA1c            |                   |
| Pre                       | 5.8 (5.6 to 6.1) | 5.6 (5.4 to 5.8) | 0.874             |
| Post                      | 5.8 (5.6 to 6.1) | 5.4 (5.2 to 5.6) | 0.874             |
| Diff                      | 0.0 (-0.1 to 0.1) | -0.05 (-0.2 to 0.0) | 0.057            |
| IL-8 (mmol/L)             |                | IL-8             |                   |
| Pre                       | 9.0 (7.7 to 10.3) | 7.5 (7.2 to 8.4) | 0.798             |
| Post                      | 9.2 (6.9 to 11.1) | 7.8 (7.2 to 8.9) | 0.798             |
| Diff                      | 0.0 (-1.5 to 1.2) | 0.2 (-1.0 to 1.5) | 0.798             |
|                          | Pre                  | Post                  | Diff                  |        |
|--------------------------|----------------------|-----------------------|-----------------------|--------|
| **MCP-1 (pg/mL)**        | 42.2 (10.3 to 59.4)  | 41.3 (11.1 to 60.2)   | 0.0 (-5.4 to 1.7)     | 0.551  |
|                          | **Pre**              | **Post**              | **Diff**              | **R**  |
|                          | 51.7 (40.9 to 70.2)  | 52.8 (45.1 to 93.7)   | 1.9 (0.2 to 17.5)     | 0.014  |
| **RANTES (pg/mL)**       | 9206 (8172 to 9833)  | 8918 (8046 to 9942)   | -161 (-730 to 677)    | 0.810  |
|                          | 8800 (8370 to 9761)  | 9164 (8651 to 10027)  | 19.09 (-633 to 1105)  | 0.41   |
| **TNFα (pg/mL)**         | 10.1 (7.8 to 13.3)   | 9.9 (6.5 to 13.9)     | 0.9 (-2.8 to 2.9)     | 0.737  |
|                          | 6.5 (6.1 to 10.9)    | 8.0 (5.8 to 11.4)     | -0.4 (-1.5 to 3.9)    | 0.66   |
Table 3 Changes from baseline to 16 weeks follow-up in plasma anthocyanin metabolites, for participants with supplementation (active) and for control participants.

| Metabolite                          | Active (n=27) Median (IQR) | Control (n=20) Median (IQR) | Active vs Control p* | Control vs Active p* |
|-------------------------------------|-----------------------------|-----------------------------|----------------------|----------------------|
| Methylpyrogallol-O-sulfate          |                             |                             |                      |                      |
| Pre                                 | 33.1 (17.5 to 52.5)         | 26.2 (10.2 to 67.6)         | 0.068                | 0.85                 |
| Post                                | 45.5 (24.1 to 104.2)        | 20.6 (7 to 65.3)            |                      |                      |
| Diff                                | 15.6 (-3.3 to 70.7)         | -1.7 (-23.8 to 13.0)        |                      | 0.14                 |
| Pyrogallol-2-O-sulfate              |                             |                             |                      |                      |
| Pre                                 | 36.4 (17.2 to 110.5)        | 58.4 (20.4 to 102.4)        | 0.001                | 0.41                 |
| Post                                | 63.8 (41.5 to 199.1)        | 35.2 (21.2 to 93.1)         |                      | 0.89                 |
| Diff                                | 17.5 (-8.3 to 106.4)        | -12.3 (-82.4 to 32.1)       |                      | 0.071                |
| Protocatechuic acid-3-O-sulfate     |                             |                             |                      |                      |
| Pre                                 | 3.5 (0.3 to 11.1)           | 5.4 (1.6 to 10.1)           | 0.007                | 0.81                 |
| Post                                | 11.0 (5.5 to 26.5)          | 6.5 (0.3 to 16.4)           |                      | 0.071                |
| Diff                                | 6.2 (0.0 to 21.6)           | 0.8 (-6.3 to 10.1)          |                      |                      |
| 1-Methylpyrogallol-O-sulfate        |                             |                             |                      |                      |
| Pre                                 | 44.7 (29.2 to 77.3)         | 60.8 (34.8 to 123)          |                      | 0.81                 |
| Post                                | 52.7 (33.6 to 97.2)         | 71.8 (30.3 to 106)          |                      | 0.699                |
| Diff                                | 12.8 (-19.6 to 32.7)        | 10.4 (-27.8 to 65.5)        | 0.14                 |                      |
| 4-Methylgallic-3-O-sulfate          |                             |                             |                      |                      |
| Pre                                 | 14.0 (5.6 to 23.8)          | 13.1 (8.5 to 28.7)          | 0.65                 | 0.25                 |
| Post                                | 12.8 (7.1 to 24.6)          | 12.3 (7.3 to 21.1)          |                      |                      |
| Diff                                | 1.6 (-7.8 to 14.3)          | -5.5 (-15.6 to 12.0)        |                      |                      |
| 4-Hydroxybenzoic acid-O-sulfate     |                             |                             |                      |                      |
| Pre                                 | 2027 (1211 to 4284)         | 2664 (1455 to 3764)         |                      |                      |
| Post                                | 1704 (772 to 3597)          | 1723 (420 to 4354)          |                      |                      |
| Diff                                | -97 (-1039 to 234)          | -924 (-2691 to 1046)        | 0.14                 | 0.26                 |
| 4-Hydroxyhippuric acid              |                             |                             |                      |                      |
| Pre                                 | 164 (93 to 272)             | 145 (117 to 275)            |                      |                      |
| Post                                | 123 (94 to 283)             | 111 (91 to 163)             |                      |                      |
| Substance                          | Pre        | Post       | Diff       | P-Value (Pre) | P-Value (Post) |
|-----------------------------------|------------|------------|------------|--------------|---------------|
| **Anthocyanin Pilot Study**       |            |            |            |              |               |
| **Diff**                          | 6 (-84 to 44) | 0.84      | -33 (-236 to 33) | 0.079    | 0.21         |
| **Protocatechuic acid**           |            |            |            |              |               |
| Pre                               | 57.5 (22.0 to 106.8) | 66.6 (35.5 to 127) |          |              |               |
| Post                              | 51.3 (29.4 to 114.2) | 48.7 (5.0 to 76.9) |          |              |               |
| Diff                              | 1.6 (-49.7 to 51.3) | 0.75      | -22.0 (-85.2 to 17.2) | 0.049    | 0.057        |
| **Pyrogallol-1-O-sulfate**        |            |            |            |              |               |
| Pre                               | 25.6 (15.3 to 61.2) | 55.1 (25.3 to 106.5) |          |              |               |
| Post                              | 52.9 (25.5 to 97.6) | 63.8 (41.4 to 94.4) |          |              |               |
| Diff                              | 18.8 (1.5 to 68.4) | 0.006     | -2.9 (-36.3 to 45.7) | 0.85     | 0.093        |
| **3,4-Dihydroxyphenylacetic acid** |          |            |            |              |               |
| Pre                               | 174 (100 to 237) | 122 (85 to 197) |          |              |               |
| Post                              | 106 (84 to 213) | 98 (75 to 163) |          |              |               |
| Diff                              | -26 (-135 to 69) | 0.203     | -33 (-67 to 2) | 0.044    | 0.97         |
| **Catechol-O-sulfate**            |            |            |            |              |               |
| Pre                               | 5518 (2718 to 8056) | 5986 (4284 to 7527) |          |              |               |
| Post                              | 4640 (3183 to 7843) | 4690 (3576 to 5627) |          |              |               |
| Diff                              | 367 (-2569 to 1608) | 0.61      | -937 (-3502 to 2010) | 0.25     | 0.67         |
| **Vanillic acid-4-O-sulfate**     |            |            |            |              |               |
| Pre                               | 30.6 (9.5 to 47.8) | 24.6 (9.6 to 39.6) |          |              |               |
| Post                              | 26.2 (9.8 to 42.3) | 22.6 (7.9 to 34.7) |          |              |               |
| Diff                              | -6.5 (-27.6 to 10.8) | 0.195     | -5.2 (-15.0 to 23.8) | 1.0      | 0.41         |
| **3-Hydroxyhippuric acid**        |            |            |            |              |               |
| Pre                               | 709 (191 to 3060) | 451 (269 to 1343) |          |              |               |
| Post                              | 339 (63 to 1233) | 162 (35 to 599) |          |              |               |
| Diff                              | -503 (-1246 to -55) | 0.002     | -183 (-1117 to 196) | 0.10     | 0.28         |
| **p-Coumaric acid-4-O-β-D-glucuronide** |          |            |            |              |               |
| Pre                               | 0.29 (0.00 to 0.52) | 0.23 (0.00 to 0.46) |          |              |               |
| Post                              | 0.21 (0.11 to 0.41) | 0.17 (0.00 to 0.30) |          |              |               |
| Diff                              | -0.07 (-0.26 to 0.24) | 0.919     | 0.01 (-0.20 to 0.20) | 0.94     | 0.84         |
| **Isovanillic acid-3-O-sulfate**  |            |            |            |              |               |
| Pre                               | 2.3 (0.0 to 8.3) | 5.5 (0.0 to 19.1) |          |              |               |
| Post                              | 2.8 (0.0 to 11.3) | 5.7 (0.3 to 14.4) |          |              |               |
|                  | Pre       | Post      | Diff       | p-value  |
|------------------|-----------|-----------|------------|----------|
| **Anthocyanin Pilot Study** |           |           |            |          |
| **Diff**         | 0.0 (-3.5 to 11.3) | 0.903     | -1.1 (-10.6 to 3.6) | 0.502   |
| **Catechol-O-1-glucuronide** |           |           |            | 0.48     |
| Pre              | 1.7 (0.0 to 9.2) | 2.2 (0.1 to 8.0) |
| Post             | 4.6 (1.6 to 14.2) | 1.1 (0.1 to 6.6) |
| Diff             | 1.5 (-1.5 to 8.8) | 0.075     | 0.1 (-2.2 to 1.7) | 0.97    |
| **Ferulic acid-4-O-β-D-glucuronide** |           |           |            | 0.14     |
| Pre              | 4.3 (0.4 to 33.4) | 7.7 (1.0 to 19.4) |
| Post             | 19.4 (2.6 to 59.3) | 5.8 (1.1 to 21.5) |
| Diff             | 5.5 (0.2 to 31.4) | 0.013     | -0.3 (-5.9 to 15.4) | 0.98    |
| **Hippuric acid** |           |           |            | 0.064    |
| Pre              | 17680 (9444 to 55008) | 24075 (11958 to 39646) |
| Post             | 15225 (8654 to 40673) | 12211 (11086 to 28936) |
| Diff             | -3572 (-18398 to 1041) | 0.068     | -2788 (-15907 to 4975) | 0.33    |
| **4-Methylcatechol-O-sulfate** |           |           |            | 0.68     |
| Pre              | 1630 (815 to 3580) | 1209 (753 to 1889) |
| Post             | 1228 (691 to 2722) | 997 (647 to 1899) |
| Diff             | -182 (-1087 to 733) | 0.47      | -221 (-617 to 255) | 0.28    |
| **4-Hydroxybenzaldehyde** |           |           |            | 0.95     |
| Pre              | 72.6 (40.3 to 130) | 81.2 (58.4 to 105) |
| Post             | 53.5 (48.9 to 93.3) | 48.7 (39.5 to 75.5) |
| Diff             | -24.8 (-56.1 to 6.5) | 0.029     | -34.3 (-52.8 to -6.8) | 0.019  |
| **Ferulic acid-4-O-sulfate** |           |           |            | 0.78     |
| Pre              | 2.3 (0.5 to 7.0) | 4.0 (0.0 to 12.3) |
| Post             | 1.9 (0.8 to 23.8) | 6.1 (1.6 to 9.7) |
| Diff             | 0.5 (-2.9 to 21.1) | 0.20      | 1.1 (-7.7 to 9.1) | 0.55    |
| **Dihydroisoferulic acid-3-O-sulfate** |           |           |            | 0.69     |
| Pre              | 7.2 (0.0 to 17.5) | 4.9 (0.0 to 14.1) |
| Post             | 9.2 (2.1 to 23.7) | 7.6 (1.0 to 19.4) |
| Diff             | 1.0 (-7.5 to 8.6) | 0.47      | 0.9 (-6.9 to 13.0) | 0.69    |
| **Isoferulic acid-3-O-sulfate** |           |           |            | 0.94     |
| Pre              | 1.1 (0.3 to 2.3) | 0.8 (0.4 to 5.7) |
| Post             | 4.5 (0.4 to 13.7) | 1.5 (0.3 to 8.6) |
|                          | Diff                | Pre        | Post       | Diff       | Pre        | Post       | Diff       |
|--------------------------|---------------------|------------|------------|------------|------------|------------|------------|
| **Anthocyanin Pilot Study** |                     |            |            |            |            |            |            |
| **Dihydroisoferulic acid-3-O-β-D-glucuronide** |                      |            |            |            |            |            |            |
| Pre                      | 19.1 (7.2 to 45.7)  | 25.8 (2.5 to 82.4) |            |            |            |            |            |
| Post                     | 20.7 (8.1 to 60.8)  | 16.1 (5.4 to 43.4) |            |            |            |            |            |
| Diff                     | 1.2 (-15.4 to 34.5) | 0.47       | -4.9 (-70.9 to 27.7) | 0.55       | 0.25       | 0.4 (-1.6 to 2.4) | 0.55       |
| **Isoferulic acid-3-O-β-D-glucuronide** |                      |            |            |            |            |            |            |
| Pre                      | 22.3 (5.2 to 67.5)  | 21.2 (1.8 to 54.6) |            |            |            |            |            |
| Post                     | 27.3 (8.5 to 136.4) | 21.3 (5.7 to 58.6) |            |            |            |            |            |
| Diff                     | 24.4 (-18.0 to 96.2)| 0.044      | 2.7 (-10.1 to 36.8) | 0.55       | 0.43       | -1.5 (-3.1 to -0.3) | 0.31       |
| **Dihydroferulic acid-4-O-sulfate** |                      |            |            |            |            |            |            |
| Pre                      | 3.7 (1.2 to 8.3)    | 1.9 (0.2 to 3.6) |            |            |            |            |            |
| Post                     | 1.6 (0.9 to 5.1)    | 2.7 (1.4 to 5.2) |            |            |            |            |            |
| Diff                     | -1.5 (-3.1 to -0.3) | 0.006      | 0.8 (-0.9 to 2.9) | 0.31       | 0.43       | 36 (-917 to 345) | 0.74       |
| **3-(3-hydroxyphenyl)propanoic acid** |                      |            |            |            |            |            |            |
| Pre                      | 805 (44 to 2377)    | 350 (14 to 1479) |            |            |            |            |            |
| Post                     | 470 (72 to 4306)    | 414 (112 to 1624) |            |            |            |            |            |
| Diff                     | 29 (-495 to 831)    | 0.43       | 36 (-917 to 345) | 0.74       | 0.43       | 36 (-917 to 345) | 0.74       |
| **m-Coumaric acid**      |                      |            |            |            |            |            |            |
| Pre                      | 111 (35 to 146)     | 84 (63 to 110) |            |            |            |            |            |
| Post                     | 55 (38 to 78)       | 58 (53 to 85) |            |            |            |            |            |
| Diff                     | -62 (-82 to 16)     | 0.014      | -28 (-58 to 2) | 0.093      | 0.014      | -28 (-58 to 2) | 0.006      |
| **o-Coumaric acid**      |                      |            |            |            |            |            |            |
| Pre                      | 218 (81 to 356)     | 125 (81 to 234) |            |            |            |            |            |
| Post                     | 87 (47 to 158)      | 81 (50 to 162) |            |            |            |            |            |
| Diff                     | -116 (-230 to -35)  | 0.00       | -36 (-111 to -1) | 0.006      | 0.00       | -36 (-111 to -1) | 0.006      |
Table 4 Changes from baseline to 16 weeks follow-up in cognitive variables, for participants with supplementation (active).

|                      | Active (n = 27) | Median (IQR) | p     |
|----------------------|----------------|--------------|-------|
| **CERAD (points)**   |                |              |       |
| **Learning**         |                |              |       |
| Pre                  | 20 (16 to 22)  |              |       |
| Post                 | 21 (17 to 25)  |              |       |
| Diff                 | 2 (-1 to 3)    |              | 0.016 |
| **Recall**           |                |              |       |
| Pre                  | 6 (4 to 8)     |              |       |
| Post                 | 7 (5 to 9)     |              |       |
| Diff                 | 1 (0 to 2)     |              | 0.00  |
| **Recognition**      |                |              |       |
| Pre                  | 20 (16 to 20)  |              |       |
| Post                 | 20 (19 to 20)  |              |       |
| Diff                 | 0 (0 to 1)     |              | 0.047 |
| **TMT A (sec)**      |                |              |       |
| Pre                  | 32 (21 to 53)  |              |       |
| Post                 | 34 (23 to 39)  |              |       |
| Diff                 | -2 (-6 to 2)   |              | 0.081 |
| **TMT B n=19 (sec)** | 85.50 (62.25 to 118) |  |       |
| Post                 | 69.50 (56 to 100.75) |  | 0.16  |
| Diff                 | -2.0 (-19.75 to 2.25) | |       |
| **STROOP (score)**   |                |              |       |
| **Word**             |                |              |       |
| Pre                  | 87 (72 to 67)  |              |       |
| Post                 | 87 (80 to 103) |              |       |
| Diff                 | 6 (1 to 10)    |              | 0.00  |
| **Color**            |                |              |       |
| Pre                  | 61(52 to 67)   |              |       |
| Post                 | 62 (54 to 69)  |              |       |
| Diff                 | 2 (-1 to 6)    |              | 0.044 |
| **Word-Color**       |                |              |       |
| Pre                  | 34 (29 to 41)  |              |       |
| Post                 | 34 (28 to 41)  |              |       |
| Diff                 | 0 (-3 to 5)    |              | 0.666 |
Legends

Figure 1

Enrolment of participants. N; number

Table 1

CAD; coronary artery disease. BMI; body mass index. IQR; interquartile range.

Table 2

RANTES; CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted). Diff; median difference between baseline and follow up serum measurements. IQR; interquartile range, mmol/L = millimol/litre, pg/mL = picomol/litre *The within group difference from baseline to study end. #The between group differences for Δ (difference from baseline to study end)

Table 3

Diff; median difference between baseline and follow up plasma measurements IQR; interquartile range, nmol/L = nanomol/litre *The within group difference from baseline to study end. #The between group differences for Δ (difference from baseline to study end)

Table 4

TMT; Trail Making Test. Diff; median difference between baseline and follow up results in cognitive tests. IQR; interquartile range.
## Supplementary Material

Table S1 Changes from baseline to 16 weeks follow-up in serum variables, for participants with supplementation (active) and for control participants.

| Variable                  | Active (n = 27) | Control (n = 20) | Active vs Control |
|---------------------------|-----------------|------------------|------------------|
|                          | 𝜇 (SD, range)   | 𝜇 (SD, range)   | 𝑝*               | 𝑝*              |
| **Cholesterol (mmol/L)**  |                |                  |                  |
| Pre                       | 4.3 (1.4, 1.3 to 6.7) | 5.0 (0.8, 3.4 to 6.5) |                  |                  |
| Post                      | 4.7 (1.4, 2.6 to 7.3) | 5.2 (0.8, 3.7 to 6.6) |                  |                  |
| Diff                      | 0.4 (0.8, -0.7 to 3.0) | 0.1 (0.5, -0.8 to 1.1) | 0.01             | 0.25             |
| **HDL (mmol/L)**          |                |                  |                  |
| Pre                       | 1.2 (0.3, 0.8 to 1.9) | 1.5 (0.5, 1 to 2.8) |                  |                  |
| Post                      | 1.2 (0.3, 0.8 to 1.8) | 1.5 (0.5, 0.9 to 2.8) |                  |                  |
| Diff                      | 0.0 (0.1, -0.1 to 0.2) | 0.1 (0.2, -0.3 to 0.4) | 0.81             | 0.204            |
| **LDL (mmol/L)**          |                |                  |                  |
| Pre                       | 2.8 (1.3, 1.2 to 5.1) | 3.3 (0.9, 1.3 to 4.7) |                  |                  |
| Post                      | 3.1 (1.4, 0.9 to 5.4) | 3.2 (0.8, 1.6 to 4.6) |                  |                  |
| Diff                      | 0.2 (0.8, -1.1 to 3) | 0.1 (0.4, -0.6 to 1) | 0.16             | 0.54             |
| **Triglycerides (mmol/L)**|                |                  |                  |
| Pre                       | 1.1 (0.5, 0.6 to 2.4) | 0.8 (0.4, 0.4 to 2) |                  |                  |
| Post                      | 1.4 (0.5, 0.5 to 5.3) | 1.2 (0.7, 0.4 to 3.2) |                  |                  |
| Diff                      | 0.2 (0.6, -3.5 to 2.9) | 0.2 (0.4, -0.4 to 1.2) | 0.05             | 0.067            |
| **Fasting glucose (mmol/L)**|              |                  |                  |
| Pre                       | 5.6 (0.8, 4.5 to 7.3) | 5.3 (0.5, 4.6 to 6.6) |                  |                  |
| Post                      | 5.7 (0.7, 4.6 to 7.2) | 5.2 (0.5, 4.3 to 6.3) |                  |                  |
| Diff                      | 0.1 (0.4, -0.6 to 0.8) | -0.2 (0.2, -0.5 to 0.3) | 0.07             | 0.005            |
| **HbA1c (%)**             |                |                  |                  |
| Pre                       | 5.8 (0.5, 4.9 to 7.9) | 5.5 (0.3, 4.8 to 6.2) |                  |                  |
| Post                      | 5.8 (0.5, 5.3 to 7.3) | 5.4 (0.4, 4.6 to 6.2) |                  |                  |
| Diff                      | -0.0 (0.2, -0.6 to 0.5) | -0.1 (0.1, -0.2 to 0.3) | 0.88             | 0.076            |
| **IL-8 (pg/mL)**          |                |                  |                  |
| Pre                       |                  |                  |                  |
| Post                      |                  |                  |                  |
| Diff                      |                  |                  |                  |
|          | Pre                        | Post                       | Diff                        |
|----------|----------------------------|----------------------------|-----------------------------|
| **MCIP-1 (pg/mL)** | 9.0 (2.1, 5.2 to 13.3)   | 7.9 (1.9, 5.54 to 13.86)  | -0.1 (1.7, -3.5 to 2.9)  |
|          | 8.9 (2.5, 3.8 to 13.6)   | 8.1 (2.0%, 4.7 to 12.9)   | 0.75 (1.7, -2.5 to 3.6)   |
|          | Diff                       |                             |                             |
| **MCP-1 (pg/mL)** | Pre 42.7 (31.4, 5.8 to 152.5) | Post 65.2 (31.2, 20.6 to 139) |                             |
|          | 0.7 (8.3, -19.4 to 24.6)  | 0.69 (8.8, -16.8, -20 to 51.6) |                             |
| **RANTES (pg/mL)** | Pre 9045 (1324, 5483 to 11846) | Post 9012 (1238, 6327 to 12559) |                             |
|          | 0.69 (8.8, -16.8, -20 to 51.6) |                             |                             |
| **TNFa (pg/mL)** | Pre 11.1 (4.4, 3.3 to 24.1) | Post 11.4 (8.0, 4.2 to 46.1) |                             |
|          | 0.85 (0.7, 4.9, -8.54 to 12.7) |                             |                             |
Table S2 Changes from baseline to 16 weeks follow-up in cognitive variables, for participants with supplementation (active).

|                          | Active (n = 27) | p     |
|--------------------------|----------------|-------|
|                          | \( \bar{x} \) (SD, range) |       |
| **CERAD (points)**       |                |       |
| Learning                 |                |       |
| Pre                      | 19.4 (4.6, 8 to 27) |       |
| Post                     | 20.8 (5.4, 8 to 29) |       |
| Diff.                    | 1.4 (3.0, -6 to 9) | 0.021 |
| **CERAD Recall**         |                |       |
| Pre                      | 5.8 (2.2, 1 to 9) |       |
| Post                     | 6.9 (2.6, 1 to 10) |       |
| Diff.                    | 1.1 (1.8, -1 to 4) | 0.00  |
| **CERAD Recognition**    |                |       |
| Pre                      | 18.7 (1.7, 14 to 20) |      |
| Post                     | 19.2 (1.6, 13 to 20) |     |
| Diff.                    | 0.5 (1.4, -4 to 4) | 0.091 |
| **TMT A (sec)**          |                |       |
| Pre                      | 35.5 (12.5, 15 to 66) |     |
| Post                     | 32.3 (12.2, 13 to 64) |   |
| Diff.                    | -3.2 (8.4, -26 to 10) | 0.059 |
| **TMT B (sec)**          |                |       |
| Pre                      | 96.9 (47.2, 48 to 226) |    |
| Post                     | 91.0 (63.7, 47 to 321) |    |
| Diff.                    | -5.9 (31.3, -70 to 98) | 0.35 |
| **STROOP (score)**       |                |       |
| Word                     |                |       |
| Pre                      | 83.4 (17.16, 48 to 115) |   |
| Post                     | 88.8 (17.9, 49 to 119) |   |
| Diff.                    | 5.4 (6.1, -7 to 21) | 0.00  |
| Color                    |                |       |
| Pre                      | 58.9 (12.9, 26 to 83) |   |
| Post                     | 61.4 (12.9, 38 to 88) |   |
| Diff.                    | 2.5 (5.5, -6 to 16) | 0.025 |
| Word-Color               |                |       |
| Pre                      | 34.0 (11, 11 to 56) |   |
| Post                     | 34.2 (12, 14 to 60) |   |
| Diff.                    | 0.2 (5.8, -14 to 11) | 0.84  |
Figure 2

[Box plot diagram showing changes in cholesterol, HDL, LDL, and triglycerides from baseline to follow-up for control and active groups. Asterisks indicate statistically significant differences.]
Figure 3

Box plots showing changes in Fasting Glucose (mmol/L) and HbA1c (%) from baseline to follow-up for control and active groups.
Figure 4

Anthocyanin Pilot Study
Figure 5
Anthocyanin Pilot Study
Figure 6

CERAD

| Learning | Recall | Recognition |
|----------|--------|-------------|

Change from Baseline to Follow-Up (points)
Figure 7
Figure 8
Legend Supplementary Material

Figure 2
Changes from baseline to 16 weeks follow-up in serum lipids, for participants with anthocyanin supplementation. mmol/L; millimole/litre

Figure 3
Changes from baseline to 16 weeks follow-up in serum fasting glucose and HbA1c, for participants with anthocyanin supplementation. HbA1c: glycosylated hemoglobin. mmol/L; millimole/litre

Figure 4
Changes from baseline to 16 weeks follow-up in serum cytokines, for participants with anthocyanin supplementation. RANTES; CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted). pg/mL = picomolar/millilitre

Figure 5
Changes from baseline to 16 weeks follow-up in plasma anthocyanin metabolites, for participants with and without anthocyanin supplementation. Measurement unit: nmol/L; nanomolar/litre, except for hippuric acid (nmol/10L) and coumaric acid-4-O-beta-D-glucuronide (nmol/0.033L).

Figure 6
Changes from baseline to 16 weeks follow-up in CERAD.

Figure 7
Changes from baseline to 16 weeks follow-up in Trail Making Test (TMT) Sec; seconds

Figure 8
Changes from baseline to 16 weeks follow-up in Stroop test.

Table S1
\[ \overline{x}; \text{mean. SD; standard deviation.} \] *The within group difference from baseline to study end.
\[ ^{\S} \text{independent samples t-test for the between group differences for } \Delta \text{ (difference from baseline to study end).} \] *With Welch correction for heteroscedasticity. RANTES; CCL-5/RANTES (regulated on activation, normal T-cell expressed and secreted). Diff; mean difference between baseline and follow-up results in serum measurements.

Table S2
\( \bar{x} \); mean. SD; standard deviation. TMT; Trail Making Test. Diff; mean difference between baseline and follow up results in cognitive tests.